Deloitte, Rady Children’s Institute for Genomic Medicine Announce Project to Accelerate Medical Sample Delivery Via Unmanned Aircraft Systems Bookmark has been added
Deloitte, Rady Children’s Institute for Genomic Medicine Announce Project to Accelerate Medical Sample Delivery Via Unmanned Aircraft Systems
The goals are to decrease delivery time to speed results and improve patient outcomes.
SAN DIEGO, Jan. 21, 2020 — Because every minute counts when children’s lives are at stake, Deloitte and Rady Children’s Institute for Genomic Medicine (RCIGM) are exploring an innovative approach to cut the time it takes to get medical samples to the laboratory using unmanned aircraft systems (UAS).
The plan calls for avoiding ground traffic delays by deploying UAS to fly genomic testing specimens to the lab to get results back to acutely ill babies and children more quickly.
“Through our work with RCIGM, we’ve seen firsthand their intense passion for helping children with rare disease and their dedication to discovering advancements to improve patient care,” said Josh Nelson, principal, Deloitte Consulting LLP, who leads Deloitte’s work with RCIGM. “This UAS project is an innovation to speed transport and delivery of samples to their lab. Together with RCIGM, we plan to go from strategy to testing to operational and develop a blueprint for other health care organizations to use.”
RCIGM has pioneered the use of rapid whole-genome sequencing to diagnose newborns and children with life-threatening rare genetic disease. “We are excited about the potential this innovative technology offers to improve health care outcomes for critically sick babies,” said Stephen Kingsmore, president and CEO of RCIGM. “By rapidly decoding a child’s DNA, we can provide medical teams with vital information to guide personalize patient care. When minutes matter, we can’t afford to have a sample delayed in transit.”
The project is currently in the planning stages. Funding and successful testing must be completed before adopting the technology for routine use.
Together, Deloitte and RCIGM, in coordination with the Federal Aviation Administration (FAA), will carefully test and validate the safety of UAS for this use. The project team will also take into consideration issues many medical and technical requirements such as temperature control and flight safety during deliveries. In addition, the UAS program will need to comply with all FAA regulations governing San Diego’s busy airspace.
As this UAS project is developed for RCIGM, Deloitte has identified other potential UAS benefits for health care organizations, such as:
- Decreased health care costs: Instead of establishing rapid genome sequencing centers at more locations, UAS medical delivery creates a way for hospitals to provide advanced testing services by sending samples to certified, accredited genomic laboratories while remaining within budget.
- Extension of subject-matter expertise to remote geographies: Often rural or remote locations do not have access to the specialty treatments that urban areas do. UAS medical delivery can bring the new capabilities to harder-to-reach areas of the country and world.
- Additional medical delivery use cases: Once delivery of samples is well established, deliveries could go beyond genome samples and apply to additional types of samples or to carrying samples over farther distances.
- Expansion of medical delivery capabilities: UAS medical delivery could enable the creation of specialty testing centers at strategically located sites. This approach could expand availability of time-sensitive advanced testing to hospitals that cannot afford their own testing centers.
“This technology opens many possibilities for providing faster diagnosis for a variety of needs. Coupling rapid sequencing tests with rapid sample transport will speed the time to precise treatment and reduce the period of uncertainty both for providers and the parents of our patients,” said Dr. Kingsmore. “More babies’ and children’s lives can be saved—this what drives us.”
“This collaboration with RCIGM is part of our ongoing commitment to private- and public-sector clients in the San Diego region,” said Nelson.
Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world’s most admired brands, including nearly 90 percent of the Fortune 500® and more than 5,000 private and middle-market companies. Our people work across the industry sectors that drive and shape today’s marketplace—delivering measurable and lasting results that help reinforce public trust in our capital markets, inspire clients to see challenges as opportunities to transform and thrive, and help lead the way toward a stronger economy and a healthy society. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. Now celebrating 175 years of service, our network of member firms spans more than 150 countries and territories. Learn how Deloitte’s more than 312,000 people worldwide make an impact that matters at www.deloitte.com.
About Rady Children’s Institute for Genomic Medicine
The Institute is leading the way in advancing precision health care for infants and children through genomic and systems medicine research. Discoveries at the Institute are enabling rapid diagnosis and targeted treatment of critically ill newborns and pediatric patients at Rady Children’s Hospital-San Diego and collaborating hospitals. The vision is to expand delivery of this life-saving technology to enable the practice of rapid precision medicine at children’s hospitals across the nation and the world. RCIGM is a subsidiary of Rady Children’s Hospital and Health Center. Learn more at www.radygenomics.org. Follow us on Twitter and LinkedIn.